Streetbeat News

Analyst Ratings

BNTX

BioNTech (NASDAQ:BNTX) has been analyzed by 8 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $102.38, with a high of $113.00 and a low of $85.00. Recent analyst actions include rating adjustments and price target changes. BioNTech faces challenges with a 23.26% revenue decline, negative net margin, and below-average ROE and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 8:02 pm

PTEN

Citigroup analyst Scott Gruber maintains a Buy rating on Patterson-UTI Energy but lowers the price target from $12.5 to $11.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:52 pm

HP

Citigroup analyst Scott Gruber maintains a Neutral rating on Helmerich & Payne (NYSE:HP) and lowers the price target from $41 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:50 pm

RVNC

Barclays analyst Balaji Prasad has downgraded Revance Therapeutics from Overweight to Equal-Weight and reduced the price target from $10 to $7.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:46 pm

MRK

Unusual options activity has been detected for Merck & Co (NYSE:MRK), with a significant bearish sentiment among large investors. Benzinga's options scanner identified 8 uncommon trades, split evenly between puts and calls, with a total bearish sentiment. The price range targeted by these trades is between $85.0 and $130.0. Merck's current stock price is $115.23, with a slight decrease of 0.01%. An analyst from Cantor Fitzgerald has lowered the rating to Overweight with a price target of $155.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 7:35 pm

WSM

Investors have taken a predominantly bearish stance on Williams-Sonoma (NYSE:WSM) through options trading, with 75% of trades being puts. The stock is currently trading at $144.19, up 6.13%, but analysts have mixed ratings with target prices ranging from $140 to $170.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 7:35 pm

HAE

CL King has initiated coverage on Haemonetics with a Buy rating and set a price target of $116, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:34 pm

ORCL

JP Morgan analyst Mark Murphy maintains a Neutral rating on Oracle (NYSE:ORCL) but raises the price target from $120 to $140.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:29 pm

TVTX

JP Morgan analyst Anupam Rama maintains an Overweight rating on Travere Therapeutics and raises the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:26 pm

APLS

JP Morgan analyst Anupam Rama maintains an Overweight rating on Apellis Pharmaceuticals but lowers the price target from $64 to $57.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:24 pm